Cyclo Therapeutics up as rare disease drug trial enrollment is on track

Cyclo Therapeutics

11/01/2023 15:30

** Shares of drug developer Cyclo Therapeutics Inc  CYTH.O 
rise ~3% to $1.97
    ** Company says it is on track to complete enrollment by end
of 2023 for late-stage study of its lead candidate Trappsol
Cyclo in treating Niemann-Pick Disease Type C (NPC) — a rare
progressive genetic disorder
    ** NPC is characterized by inability of the body to
transport cholesterol and other fatty substances (lipids) inside
of cells
    ** Patient enrollment and dosing for a mid-stage study for
the drug to treat early Alzheimer's disease also underway - CYTH
    ** Stock lost ~62% last year
 (Reporting by Sriparna Roy)
 ((Sriparna.Roy@thomsonreuters.com))